BridgeBio Pharma Announces Inducement Grants to New Hires

Friday 11th of April 2025 20:01:00

BridgeBio Pharma Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Palo Alto, CA, April 25, 2023 – BridgeBio Pharma, Inc. (NASDAQ: BBIO), a biopharmaceutical company focused on genetic diseases, today announced that it has granted equity awards to certain new employees under its equity incentive plan, as required by NASDAQ Listing Rule 5635(c)(4).

The inducement grants were approved by the Compensation Committee of the Board of Directors and were made as an inducement to these individuals to join the company. The number of shares of common stock subject to the inducement grants is as follows:

  • [Employee 1]: 10,000 shares, with a grant date fair value of approximately $143,000;
  • [Employee 2]: 15,000 shares, with a grant date fair value of approximately $214,500;
  • [Employee 3]: 20,000 shares, with a grant date fair value of approximately $286,000.

The equity awards are subject to the terms and conditions of the company's equity incentive plan and the applicable award agreements. The grants are also subject to the vesting schedule and other terms and conditions set forth in the applicable award agreements.

About BridgeBio Pharma, Inc. BridgeBio Pharma, Inc. is a biopharmaceutical company founded in 2015 to develop genetic medicines for patients with rare genetic diseases. The company's lead programs are focused on developing treatments for genetic diseases such as achondroplasia, Muenke syndrome, and others. BridgeBio Pharma is headquartered in Palo Alto, California. For more information, please visit www.bridgebio.com.